Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients.

Schuelke MR, Bassiri H, Behrens EM, Canna S, Croy C, DiNofia A, Gollomp K, Grupp S, Lambert M, Lambrix A, Maude SL, Myers R, Newman H, Petrosa W, Seif A, Sullivan KE, Teachey DT, Diorio C. Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients. Blood Adv. 2023 09 26; 7(18):5603-5607.

View in: PubMed

subject areas

Antibodies, Monoclonal
Antibodies, Neutralizing
Child
Humans

authors with profiles

Kathleen Sullivan, APRN, PMHCNS-BC

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support